Immunogenes receives $1 million from Hungary's government
This article was originally published in Scrip
Immunogenes, a Budapest-based biopharmaceutical company, has received Ft171 million ($1.1 million) funding under the national technology programme. It won one of the tenders announced last October to boost R&D projects in areas including biotechnology, human and veterinary medicine, environmental science and nanotechnology. The total budget for projects in the field was Ft14 billion. Immunogenes was established to use a proprietary technology that allows genetic alterations in animals, leading to a substantial increase in antibody production and a shorter process time, of up to 30%. Other benefits of the technology include requiring fewer immunisations, using smaller quantities of antigens, and an up to 40% saving in costs, the company says.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.